Finanzen von vTv Therapeutics Inc (VTVT)VTVTvTv Therapeutics Inc

Evaluating the bottom line, vTv Therapeutics Inc maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 25.33%, while the net margin is 30.08%. These profitability ratios, combined with a Return on Equity (ROE) of -11.69%, provide a clear picture of how effectively VTVT converts its operational activities into shareholder value.

In the context of the broader market, VTVT competes directly with industry leaders such as CPIX and AARD. With a market capitalization of $127.95M, it holds a significant position in the sector. When comparing efficiency, VTVT's gross margin of N/A stands against CPIX's 100.00% and AARD's N/A. Such benchmarking helps identify whether vTv Therapeutics Inc is trading at a premium or discount relative to its financial performance.

The company reported a significant revenue increase in Q1 2026 with $36.84 million, but Q2 2026 showed a decline in cash reserves to $86.6 million, raising concerns about financial stability. The gross margin has been consistently at 100% in recent quarters, indicating strong product profitability when revenues are generated.